Literature DB >> 30155607

Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.

Claudio Semplicini1,2, Pascaline Letard3, Marie De Antonio2, Nadjib Taouagh4, Barbara Perniconi4, Françoise Bouhour5, Andoni Echaniz-Laguna6, David Orlikowski7,8, Sabrina Sacconi9,10, Emmanuelle Salort-Campana11, Guilhem Solé12,13, Fabien Zagnoli14, Dalil Hamroun15, Roseline Froissart16, Catherine Caillaud3,17, Pascal Laforêt18,19.   

Abstract

Pompe disease (PD) is caused by a deficiency of lysosomal acid α-glucosidase resulting from mutations in the GAA gene. The clinical spectrum ranges from a rapidly fatal multisystemic disorder (classic PD, onset < 1 year) to a milder adult onset myopathy. The aims of this study were to characterize the GAA mutations, to establish the disease epidemiology, and to identify potential genotype-phenotype correlations in French late-onset PD patients (onset ≥ 2 years) diagnosed since the 1970s. Data were collected from the two main laboratories involved in PD diagnosis and from the French Pompe registry. Two hundred forty-six patients (130 females and 116 males) were included, with a mean age at diagnosis of 43 years. Eighty-three different mutations were identified in the GAA gene, among which 28 were novel. These variants were spread all over the sequence and included 42 missense (one affecting start codon), 8 nonsense, 15 frameshift, 14 splice mutations, 3 small in-frame deletions, and one large deletion. The common c.-32-13T>G mutation was detected in 151/170 index cases. Other frequent mutations included the exon 18 deletion, the c.525del, and the missense mutations c.1927G>A (p.Gly643Arg) and c.655G>A (p.Gly219Arg). Patients carrying the c.-32-13T>G mutation had an older mean age at onset than patients non-exhibiting this mutation (36 versus 25 years). Patients with the same genotype had a highly variable age at onset. We estimated the frequency of late-onset PD in France around 1/69,927 newborns. In conclusion, we characterized the French cohort of late-onset PD patients through a nationwide study covering more than 40 years.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30155607     DOI: 10.1007/s10545-018-0243-7

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  38 in total

1.  Timing of diagnosis of patients with Pompe disease: data from the Pompe registry.

Authors:  Priya S Kishnani; Hernán M Amartino; Christopher Lindberg; Timothy M Miller; Amanda Wilson; Joan Keutzer
Journal:  Am J Med Genet A       Date:  2013-08-30       Impact factor: 2.802

2.  A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease.

Authors:  Priya S Kishnani; Wuh-Liang Hwu; Hanna Mandel; Marc Nicolino; Florence Yong; Deyanira Corzo
Journal:  J Pediatr       Date:  2006-05       Impact factor: 4.406

3.  Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations.

Authors:  Rachel E Palmer; Hernan M Amartino; Gabriela Niizawa; Mariana Blanco; Robert J Pomponio; Nestor A Chamoles
Journal:  Neuromuscul Disord       Date:  2006-10-23       Impact factor: 4.296

4.  Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening.

Authors:  Yin-Hsiu Chien; Ni-Chung Lee; Hsiang-Ju Huang; Beth L Thurberg; Fuu-Jen Tsai; Wuh-Liang Hwu
Journal:  J Pediatr       Date:  2011-01-13       Impact factor: 4.406

Review 5.  The natural course of non-classic Pompe's disease; a review of 225 published cases.

Authors:  Léon P F Winkel; Marloes L C Hagemans; Pieter A van Doorn; M Christa B Loonen; Wim J C Hop; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2005-08       Impact factor: 4.849

6.  A randomized study of alglucosidase alfa in late-onset Pompe's disease.

Authors:  Ans T van der Ploeg; Paula R Clemens; Deyanira Corzo; Diana M Escolar; Julaine Florence; Geert Jan Groeneveld; Serge Herson; Priya S Kishnani; Pascal Laforet; Stephen L Lake; Dale J Lange; Robert T Leshner; Jill E Mayhew; Claire Morgan; Kenkichi Nozaki; Dorothy J Park; Alan Pestronk; Barry Rosenbloom; Alison Skrinar; Carine I van Capelle; Nadine A van der Beek; Melissa Wasserstein; Sasa A Zivkovic
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

7.  Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.

Authors:  C Angelini; C Semplicini; S Ravaglia; B Bembi; S Servidei; E Pegoraro; M Moggio; M Filosto; E Sette; G Crescimanno; P Tonin; R Parini; L Morandi; G Marrosu; G Greco; O Musumeci; G Di Iorio; G Siciliano; M A Donati; F Carubbi; M Ermani; T Mongini; A Toscano
Journal:  J Neurol       Date:  2011-11-12       Impact factor: 4.849

8.  A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II).

Authors:  N Raben; R C Nichols; F Martiniuk; P H Plotz
Journal:  Hum Mol Genet       Date:  1996-07       Impact factor: 6.150

9.  Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II.

Authors:  A L E Montalvo; B Bembi; M Donnarumma; M Filocamo; G Parenti; M Rossi; L Merlini; E Buratti; P De Filippi; A Dardis; M Stroppiano; G Ciana; M G Pittis
Journal:  Hum Mutat       Date:  2006-10       Impact factor: 4.878

10.  A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.

Authors:  Andreas Herzog; Ralf Hartung; Arnold J J Reuser; Pia Hermanns; Heiko Runz; Nesrin Karabul; Seyfullah Gökce; Joachim Pohlenz; Christoph Kampmann; Christina Lampe; Michael Beck; Eugen Mengel
Journal:  Orphanet J Rare Dis       Date:  2012-06-07       Impact factor: 4.123

View more
  10 in total

Review 1.  Molecular genetics of Pompe disease: a comprehensive overview.

Authors:  Paolo Peruzzo; Eleonora Pavan; Andrea Dardis
Journal:  Ann Transl Med       Date:  2019-07

2.  Urine glucose tetrasaccharide: A good biomarker for glycogenoses type II and III? A study of the French cohort.

Authors:  Monique Piraud; Magali Pettazzoni; Marie de Antonio; Christine Vianey-Saban; Roseline Froissart; Brigitte Chabrol; Sarah Young; Pascal Laforêt
Journal:  Mol Genet Metab Rep       Date:  2020-05-01

3.  GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry.

Authors:  Arnold J J Reuser; Ans T van der Ploeg; Yin-Hsiu Chien; Juan Llerena; Mary-Alice Abbott; Paula R Clemens; Virginia E Kimonis; Nancy Leslie; Sonia S Maruti; Bernd-Jan Sanson; Roberto Araujo; Magali Periquet; Antonio Toscano; Priya S Kishnani
Journal:  Hum Mutat       Date:  2019-08-07       Impact factor: 4.878

4.  Clinical manifestations and acid alpha-glucosidase mutation characterisation of a cohort of patients with late-onset Pompe disease in eastern China.

Authors:  Hui-Hui Zhao; Zhi Ma; Zi-Xuan Ying; Feng-Nan Niu; Mao-Tao Luo; Zheng Wang; Xi Cheng; Qian-Qian Zhang; Qi Niu
Journal:  Ann Transl Med       Date:  2021-12

5.  L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report.

Authors:  Valentina Rovelli; Juri Zuvadelli; Marta Piotto; Andrea Scopari; Alice Re Dionigi; Vittoria Ercoli; Sabrina Paci; Graziella Cefalo; Elisabetta Salvatici; Giuseppe Banderali
Journal:  Ital J Pediatr       Date:  2022-03-28       Impact factor: 2.638

6.  Non-specificity of symptoms in infantile-onset Pompe disease may delay the diagnosis and institution of treatment.

Authors:  Udara Dilrukshi Senarathne; Eresha Jasinge; Sarojini Viknarajah Mohan; Samantha Waidyanatha
Journal:  BMJ Case Rep       Date:  2022-03-09

Review 7.  Detection of Structural Variants by NGS: Revealing Missing Alleles in Lysosomal Storage Diseases.

Authors:  Valentina La Cognata; Sebastiano Cavallaro
Journal:  Biomedicines       Date:  2022-07-29

8.  Broad variation in phenotypes for common GAA genotypes in Pompe disease.

Authors:  Monica Y Niño; Stijn L M In't Groen; Douglas O S de Faria; Marianne Hoogeveen-Westerveld; Hannerieke J M P van den Hout; Ans T van der Ploeg; Atze J Bergsma; W W M Pim Pijnappel
Journal:  Hum Mutat       Date:  2021-09-08       Impact factor: 4.700

9.  Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease-associated variants, common sequence variants, and results from newborn screening.

Authors:  Douglas O S de Faria; Stijn L M In 't Groen; Marianne Hoogeveen-Westerveld; Monica Y Nino; Ans T van der Ploeg; Atze J Bergsma; W W M Pim Pijnappel
Journal:  Hum Mutat       Date:  2020-12-21       Impact factor: 4.878

10.  Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.

Authors:  Filomena Napolitano; Giorgia Bruno; Chiara Terracciano; Giuseppina Franzese; Nicole Piera Palomba; Federica Scotto di Carlo; Elisabetta Signoriello; Paolo De Blasiis; Stefano Navarro; Alessandro Gialluisi; Mariarosa Anna Beatrice Melone; Simone Sampaolo; Teresa Esposito
Journal:  Int J Mol Sci       Date:  2021-03-31       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.